H. R. 6344—39
SEC. 1102. CONTROLLED SUBSTANCES ACT AMENDMENTS. 
Section 303(g)(2) of the Controlled Substances Act (21 U.S.C. 
823(g)(2)) is amended—
(1) in subparagraph (B)(iii), by striking ‘‘except that the’’ 
and inserting the following: ‘‘unless, not sooner than 1 year 
after the date on which the practitioner submitted the initial 
notification, the practitioner submits a second notification to 
the Secretary of the need and intent of the practitioner to 
treat up to 100 patients. A second notification under this clause 
shall contain the certifications required by clauses (i) and (ii) 
of this subparagraph. The’’; and 
(2) in subparagraph (J)—
(A) in clause (i), by striking ‘‘thereafter’’ and all that 
follows through the period and inserting ‘‘thereafter.’’; 
(B) in clause (ii), by striking ‘‘Drug Addiction Treat-
ment Act of 2000’’ and inserting ‘‘Office of National Drug 
Control Policy Reauthorization Act of 2006’’; and 
(C) in clause (iii), by striking ‘‘this paragraph should 
not remain in effect, this paragraph ceases to be in effect’’ 
and inserting ‘‘subparagraph (B)(iii) should be applied by 
limiting the total number of patients a practitioner may 
treat to 30, then the provisions in such subparagraph 
(B)(iii) permitting more than 30 patients shall not apply, 
effective’’. 
SEC. 1103. REPORT ON LAW ENFORCEMENT INTELLIGENCE SHARING. 
Not later than 180 days after the date of enactment of this 
Act, the Director shall submit to Congress a report—
(1) evaluating existing and planned law enforcement intel-
ligence systems used by Federal, State, local, and tribal law 
enforcement agencies responsible for drug trafficking and drug 
production enforcement; and 
(2) addressing—
(A) the current law enforcement intelligence systems 
used by Federal, State, local, and tribal law enforcement 
agencies; 
(B) the compatibility of such systems in ensuring access 
and availability of law enforcement intelligence to Federal, 
State, local, and tribal law enforcement; 
(C) the extent to which Federal, State, local, and tribal 
law enforcement are sharing law enforcement intelligence 
information to assess current threats and design appro-
priate enforcement strategies; and 
(D) the measures needed to ensure and to promote 
effective information sharing among law enforcement intel-
ligence systems operated by Federal, State, local, and tribal 
law enforcement agencies responsible for drug trafficking 
and drug production enforcement. 
SEC. 1104. REQUIREMENT FOR SOUTH AMERICAN HEROIN STRATEGY. 
(a) IN GENERAL.—Not later than 90 days after the date of 
enactment of this Act, the Director, in coordination with the Sec-
retary of State, shall submit to Congress a comprehensive strategy 
that addresses the increased threat from South American heroin, 
and in particular Colombian heroin, and the emerging threat from 
opium poppy grown in Peru and often intended for transit to 
Columbia for processing into heroin.
H. R. 6344—40
(b) CONTENTS.—The strategy submitted under subsection (a) 
shall include—
(1) opium eradication efforts to eliminate the problem at 
the source to prevent heroin from entering the stream of com-
merce; 
(2) interdiction and precursor chemical controls; 
(3) demand reduction and treatment; 
(4) alternative development programs, including direct 
assistance to regional governments to demobilize and provide 
alternative livelihoods to former members of insurgent or other 
groups engaged in heroin, cocoa, or other illicit drug production 
or trafficking; 
(5) efforts to inform and involve local citizens in the pro-
grams described in paragraphs (1) through (4), such as through 
leaflets advertising rewards for information; and 
(6) an assessment of the specific level of funding and 
resources necessary to simultaneously address the threat from 
South American heroin and the threat from Colombian and 
Peruvian coca. 
(c) TREATMENT OF CLASSIFIED OR LAW ENFORCEMENT SENSITIVE 
INFORMATION.—Any content of the strategy submitted under sub-
section (a) that involves information classified under criteria estab-
lished by an Executive order, or whose public disclosure, as deter-
mined by the Director or the head of any relevant Federal agency, 
would be detrimental to the law enforcement of national security 
activities of any Federal, foreign, or international agency, shall 
be presented to Congress separately from the rest of the strategy. 
SEC. 1105. MODEL ACTS. 
(a) IN GENERAL.—The Director of the Office of National Drug 
Control Policy shall provide for or shall enter into an agreement 
with a non-profit corporation that is described in section 501(c)(3) 
of the Internal Revenue Code of 1986 and exempt from tax under 
section 501(a) of such Code to—
(1) advise States on establishing laws and policies to 
address alcohol and other drug issues, based on the model 
State drug laws developed by the President’s Commission on 
Model State Drug Laws in 1993; and 
(2) revise such model State drug laws and draft supple-
mentary model State laws to take into consideration changes 
in the alcohol and drug abuse problems in the State involved. 
(b) AUTHORIZATION OF APPROPRIATIONS.—There is authorized 
to be appropriated to carry out this subsection $1,500,000 for each 
of fiscal years 2007 through 2011. 
SEC. 1106. STUDY ON IATROGENIC ADDICTION ASSOCIATED WITH 
PRESCRIPTION OPIOID ANALGESIC DRUGS. 
(a) IN GENERAL.—
(1) STUDY.—The Director of the Office of National Drug 
Control Policy shall request the Institute of Medicine of the 
National Academy of Sciences to enter into an agreement under 
which the Institute agrees to study certain aspects of iatrogenic 
addiction to prescription opioid analgesics included in schedules 
II and III of the Controlled Substances Act (21 U.S.C. 812). 
(2) IATROGENIC ADDICTION.—In this section, the term ‘‘iatro-
genic addiction’’ means an addiction developed from the use 
of an opioid analgesic by an individual with no previous history 
of any addiction, who has lawfully obtained and used the drug
H. R. 6344—41
for a legitimate medical purpose by administration from, or 
pursuant to the prescription or order of, an individual practi-
tioner acting in the usual course of professional practice. 
(b) REQUIREMENTS.—The study conducted pursuant to this sec-
tion shall assess the current scientific literature to determine, if 
possible—
(1) the rate of iatrogenic addiction associated with the 
appropriate use of prescription drugs described in subsection 
(a); 
(2) the impact of iatrogenic addiction associated with the 
appropriate use of prescription drugs described in subsection 
(a) on the individual, the prescriber, other patients, and society 
in general; 
(3) the comparative abuse liability of prescription drugs 
described in subsection (a) when used properly by the ultimate 
user for a legitimate medical purpose; and 
(4)(A) what types of prospective or retrospective studies 
should be undertaken to determine the rate of iatrogenic addic-
tion associated with the appropriate use of the prescription 
drugs described in subsection (a); and 
(B) a feasible timeline for conducting and reporting such 
studies, should the current state of the scientific literature 
be insufficient to determine the rate, impact, and comparative 
abuse liability of prescription drugs described in subsection 
(a). 
(c) REPORT.—Not later than 1 year after the date of enactment 
of this Act, the Director of the Office of National Drug Control 
Policy shall ensure that the agreement under subsection (a) provides 
for the submission of a report to the Congress on the status of 
the study conducted pursuant to this section. 
SEC. 1107. REQUIREMENT FOR STRATEGY TO STOP INTERNET ADVER-
TISING 
OF 
PRESCRIPTION 
MEDICINES 
WITHOUT 
A 
PRESCRIPTION. 
Not later than 120 days after the date of the enactment of 
this Act, the Director of the Office of National Drug Control Policy 
shall submit to Congress a strategy to stop advertisements that 
provide information about obtaining over the Internet drugs (as 
defined in section 702(3) of the Office of National Drug Control 
Policy Reauthorization Act of 1998) for which a prescription is 
required without the use of such a lawful prescription. 
SEC. 1108. REQUIREMENT FOR STUDY ON DIVERSION AND INAPPRO-
PRIATE USES OF PRESCRIPTION DRUGS. 
Not later than 90 days after the date of enactment of this 
Act, the Director of the Office of National Drug Control Policy, 
in consultation with the Secretary of Health and Human Services, 
shall submit to Congress a report that includes a plan to conduct 
a study on the illegal diversion and inappropriate uses of prescrip-
tion drugs, including the following: 
(1) Methods to utilize both public use surveys that are 
in existence as of the date of enactment of this Act and other 
surveys to provide appropriate baseline data on the natural 
history of diversion and abuse of prescription drugs that are 
included in schedules under the Controlled Substances Act 
to evaluate the extent and nature of potential problems with 
such use to guide corrective actions which may reduce such 
problems without unintentionally hindering access to these
H. R. 6344—42
drugs for legitimate medical purposes. Specifically, other sur-
veys to be considered are those that address the abuse of 
these substances on a regional or national basis, and those 
that address the diversion of these substances on a regional 
or national basis. 
(2) A scientifically based analysis of the relative contribu-
tion of both innate and acquired genetic factors, environmental 
factors, psychological factors, and drug characteristics that con-
tribute to addiction to prescription drugs. 
SEC. 1109. REQUIREMENT FOR AFGHAN HEROIN STRATEGY. 
(a) IN GENERAL.—Not later than 90 days after the date of 
the enactment of this Act, the Director of the Office of National 
Drug Control Policy shall submit to the Congress a comprehensive 
strategy that addresses the increased threat from Afghan heroin. 
(b) CONTENTS.—The strategy shall include—
(1) opium crop eradication efforts to eliminate the problem 
at the source to prevent heroin from entering the stream of 
commerce; 
(2) destruction or other direct elimination of stockpiles 
of heroin and raw opium, and heroin production and storage 
facilities; 
(3) interdiction and precursor chemical controls; 
(4) demand reduction and treatment; 
(5) alternative development programs; 
(6) measures to improve cooperation and coordination 
between Federal Government agencies, and between such agen-
cies, agencies of foreign governments, and international 
organizations with responsibility for the prevention of heroin 
production in, or trafficking out of, Afghanistan; and 
(7) an assessment of the specific level of funding and 
resources necessary to significantly reduce the production and 
trafficking of heroin. 
(c) TREATMENT OF CLASSIFIED OR LAW ENFORCEMENT SENSITIVE 
INFORMATION.—Any content of the strategy that involves informa-
tion classified under criteria established by an Executive order, 
or whose public disclosure, as determined by the Director or the 
head of any relevant Federal agency, would be detrimental to the 
law enforcement or national security activities of any Federal, for-
eign, or international agency, shall be presented to Congress sepa-
rately from the rest of the strategy. 
SEC. 1110. REQUIREMENT FOR SOUTHWEST BORDER COUNTER-
NARCOTICS STRATEGY. 
(a) IN GENERAL.—Not later than 120 days after the date of 
enactment of this Act, and every 2 years thereafter, the Director 
of National Drug Control Policy shall submit to the Congress a 
Southwest Border Counternarcotics Strategy. 
(b) 
PURPOSES.—The 
Southwest 
Border 
Counternarcotics 
Strategy shall—
(1) set forth the Government’s strategy for preventing the 
illegal trafficking of drugs across the international border 
between the United States and Mexico, including through ports 
of entry and between ports of entry on that border; 
(2) state the specific roles and responsibilities of the rel-
evant National Drug Control Program agencies (as defined 
in section 702 of the Office of National Drug Control Policy
H. R. 6344—43
Reauthorization Act of 1998 (21 U.S.C. 1701)) for implementing 
that strategy; and 
(3) identify the specific resources required to enable the 
relevant National Drug Control Program agencies to implement 
that strategy. 
(c) SPECIFIC CONTENT RELATED TO DRUG TUNNELS BETWEEN 
THE UNITED STATES AND MEXICO.—The Southwest Border Counter-
narcotics Strategy shall include—
(1) a strategy to end the construction and use of tunnels 
and subterranean passages that cross the international border 
between the United States and Mexico for the purpose of illegal 
trafficking of drugs across such border; and 
(2) recommendations for criminal penalties for persons who 
construct or use such a tunnel or subterranean passage for 
such a purpose. 
(d) CONSULTATION WITH OTHER AGENCIES.—The Director shall 
issue the Southwest Border Counternarcotics Strategy in consulta-
tion with the heads of the relevant National Drug Control Program 
agencies. 
(e) LIMITATION.—The Southwest Border Counternarcotics 
Strategy shall not change existing agency authorities or the laws 
governing interagency relationships, but may include recommenda-
tions about changes to such authorities or laws. 
(f) REPORT TO CONGRESS.—The Director shall provide a copy 
of the Southwest Border Counternarcotics Strategy to the appro-
priate congressional committees (as defined in section 702 of the 
Office of National Drug Control Policy Reauthorization Act of 1998 
(21 U.S.C. 1701)), and to the Committee on Armed Services and 
the Committee on Homeland Security of the House of Representa-
tives, and the Committee on Homeland Security and Governmental 
Affairs and the Committee on Armed Services of the Senate. 
(g) TREATMENT OF CLASSIFIED OR LAW ENFORCEMENT SENSITIVE 
INFORMATION.—Any content of the Southwest Border Counter-
narcotics Strategy that involves information classified under criteria 
established by an Executive order, or whose public disclosure, as 
determined by the Director or the head of any relevant National 
Drug Control Program agency, would be detrimental to the law 
enforcement or national security activities of any Federal, State, 
local, or tribal agency, shall be presented to Congress separately 
from the rest of the strategy. 
SEC. 1111. REQUIREMENT FOR SCIENTIFIC STUDY OF MYCOHERBICIDE 
IN ILLICIT DRUG CROP ERADICATION. 
(a) REQUIREMENT.—Not later than 90 days after the date of 
enactment of this Act, the Director of the Office of National Drug 
Control Policy shall submit to the Congress a report that includes 
a plan to conduct, on an expedited basis, a scientific study of 
the use of mycoherbicide as a means of illicit drug crop elimination 
by an appropriate Government scientific research entity, including 
a complete and thorough scientific peer review. The study shall 
include an evaluation of the likely human health and environmental 
impacts of mycoherbicides derived from fungus naturally existing 
in the soil. 
(b) STUDY.—The study required by this section shall be con-
ducted in United States territory and not in any foreign country.
H. R. 6344—44
SEC. 1112. REQUIREMENT FOR STUDY OF STATE PRECURSOR CHEM-
ICAL CONTROL LAWS. 
(a) STUDY.—The Director of National Drug Control Policy, in 
consultation with the National Alliance for Model State Drug Laws, 
shall conduct a study of State laws with respect to precursor chem-
ical controls. 
(b) REPORT.—Not later than 6 months after the date of the 
enactment of this Act, the Director of National Drug Control Policy 
shall submit a report to Congress on the results of the study 
under subsection (a), including—
(1) a comparison of the State laws studied and the effective-
ness of each such law; and 
(2) a list of best practices observed with respect to such 
laws. 
SEC. 1113. REQUIREMENT FOR STUDY OF DRUG ENDANGERED CHIL-
DREN PROGRAMS. 
(a) STUDY.—The Director of National Drug Control Policy shall 
conduct a study of methamphetamine-related activities that are 
conducted by different Drug Endangered Children programs 
administered by States. 
(b) REPORT.—Not later than 6 months after the date of the 
enactment of this Act, the Director of National Drug Control Policy 
shall submit to Congress a report on the results of the study 
under subsection (a). Such report shall include—
(1) an analysis of the best practices of the activities studied; 
and 
(2) recommendations for establishing a national policy to 
address drug endangered children, based on the Drug Endan-
gered Children programs administered by States. 
(c) DEFINITIONS.—In this section—
(1) the term ‘‘methamphetamine-related activity’’ means 
any activity related to the production, use, or effects of meth-
amphetamine; and 
(2) the term ‘‘drug endangered children’’ means children 
whose physical, mental, or emotional health are at risk because 
of the production, use, or effects of methamphetamine by 
another person. 
SEC. 1114. STUDY ON DRUG COURT HEARINGS IN NONTRADITIONAL 
PLACES. 
(a) FINDING.—Congress finds that encouraging drug courts and 
schools to enter into partnerships that allow students to see the 
repercussions of drug abuse by non-violent offenders may serve 
as a strong deterrent and promote demand reduction. 
(b) STUDY.—The Director of the Office of National Drug Control 
Policy shall conduct a study on drug court programs that conduct 
hearings in nontraditional public places, such as schools. At a 
minimum, the study shall evaluate similar programs in operation, 
such as the program operated in the Fourth Judicial District Drug 
Court, in Washington County, Arkansas. 
(c) REQUIREMENT.—At the same time the President submits 
to Congress the National Drug Control Strategy due February 1, 
2007, pursuant to section 706 of the Office of National Drug Control 
Policy Reauthorization Act of 1998, the President shall submit 
to Congress a report on the study conducted under subsection 
(b). The report shall include an evaluation of the results of the
H. R. 6344—45
study and such recommendations as the President considers appro-
priate. 
(d) DEMAND REDUCTION.—In this section, the term ‘‘demand 
reduction’’ has the meaning provided in section 702(1) of the Office 
of National Drug Control Policy Reauthorization Act of 1998 (21 
U.S.C. 1701(1)). 
SEC. 1115. REPORT ON TRIBAL GOVERNMENT PARTICIPATION IN 
HIDTA PROCESS. 
(a) REPORT
REQUIREMENT.—The Director of the Office of 
National Drug Control Policy shall prepare a report for Congress 
on the representation of tribal governments in the High Intensity 
Drug Trafficking Areas Program and in high intensity drug traf-
ficking areas designated under that Program. The report shall 
include—
(1) a list of the tribal governments represented in the 
Program and a description of the participation by such govern-
ments in the Program; 
(2) an explanation of the rationale for the level of represen-
tation by such governments; and 
(3) recommendations by the Director for methods for 
increasing the number of tribal governments represented in 
the Program. 
(b) DEADLINE.—The report prepared under subsection (a) shall 
be submitted not later than 1 year after the date of the enactment 
of this Act. 
(c) DEFINITION.—In this section, the term ‘‘High Intensity Drug 
Trafficking Areas Program’’ means the program established under 
section 707 of the Office of National Drug Control Policy Reauthor-
ization Act of 1998 (21 U.S.C. 1706) 
SEC. 1116. REPORT ON SCHOOL DRUG TESTING. 
(a) REPORT REQUIREMENT.—The Director of National Drug Con-
trol Policy shall prepare a report on drug testing in schools. The 
report shall include a list of secondary schools that have initiated 
drug testing from among those schools that have attended con-
ferences on drug testing sponsored by the Office of National Drug 
Control Policy. 
(b) DEADLINE.—Not later than 120 days after the date of the 
enactment of this Act, the Director of National Drug Control Policy 
shall submit to Congress the report required under subsection (a). 
SEC. 1117. REPORT ON ONDCP PERFORMANCE BONUSES. 
(a) REPORT REQUIREMENT.—The Director of National Drug Con-
trol Policy shall prepare a report on performance bonuses at the 
Office of National Drug Control Policy. The report shall include 
a list of employees who received performance bonuses, and the 
amount of such bonuses, for the period beginning on October 1, 
2004, and ending on the date of submission of the report. 
(b) DEADLINE.—Not later than 120 days after the date of the 
enactment of this Act, the Director of National Drug Control Policy 
shall submit to Congress the report required under subsection (a). 
SEC. 1118. REQUIREMENT FOR DISCLOSURE OF FEDERAL SPONSOR-
SHIP OF ALL FEDERAL ADVERTISING OR OTHER COMMU-
NICATION MATERIALS. 
Section 712 is amended to read as follows:
H. R. 6344—46
‘‘SEC. 712. REQUIREMENT FOR DISCLOSURE OF FEDERAL SPONSOR-
SHIP OF ALL FEDERAL ADVERTISING OR OTHER COMMU-
NICATION MATERIALS. 
‘‘(a) REQUIREMENT.—Each advertisement or other communica-
tion paid for by the Office, either directly or through a contract 
awarded by the Office, shall include a prominent notice informing 
the target audience that the advertisement or other communication 
is paid for by the Office. 
‘‘(b) ADVERTISEMENT OR OTHER COMMUNICATION.—In this sec-
tion, the term ‘advertisement or other communication’ includes—
‘‘(1) an advertisement disseminated in any form, including 
print or by any electronic means; and 
‘‘(2) a communication by an individual in any form, 
including speech, print, or by any electronic means.’’. 
SEC. 1119. AWARDS FOR DEMONSTRATION PROGRAMS BY LOCAL PART-
NERSHIPS TO COERCE ABSTINENCE IN CHRONIC HARD-
DRUG 
USERS 
UNDER 
COMMUNITY 
SUPERVISION 
THROUGH THE USE OF DRUG TESTING AND SANCTIONS. 
At the end of the Act, insert the following: 
‘‘SEC. 716. AWARDS FOR DEMONSTRATION PROGRAMS BY LOCAL PART-
NERSHIPS TO COERCE ABSTINENCE IN CHRONIC HARD-
DRUG USERS UNDER COMMUNITY SUPERVISION THROUGH 
THE USE OF DRUG TESTING AND SANCTIONS. 
‘‘(a) AWARDS REQUIRED.—The Director shall make competitive 
awards to fund demonstration programs by eligible partnerships 
for the purpose of reducing the use of illicit drugs by chronic 
hard-drug users living in the community while under the super-
vision of the criminal justice system. 
‘‘(b) USE OF AWARD AMOUNTS.—Award amounts received under 
this section shall be used—
‘‘(1) to support the efforts of the agencies, organizations, 
and researchers included in the eligible partnership; 
‘‘(2) to develop and field a drug testing and graduated 
sanctions program for chronic hard-drug users living in the 
community under criminal justice supervision; and 
‘‘(3) to assist individuals described in subsection (a) by 
strengthening rehabilitation efforts through such means as job 
training, drug treatment, or other services. 
‘‘(c) ELIGIBLE PARTNERSHIP DEFINED.—In this section, the term 
‘eligible partnership’ means a working group whose application 
to the Director—
‘‘(1) identifies the roles played, and certifies the involve-
ment of, two or more agencies or organizations, which may 
include—
‘‘(A) State, local, or tribal agencies (such as those car-
rying out police, probation, prosecution, courts, corrections, 
parole, or treatment functions); 
‘‘(B) Federal agencies (such as the Drug Enforcement 
Agency, the Bureau of Alcohol, Tobacco, Firearms, and 
Explosives, and United States Attorney offices); and 
‘‘(C) community-based organizations; 
‘‘(2) includes a qualified researcher; 
‘‘(3) includes a plan for using judicial or other criminal 
justice authority to administer drug tests to individuals 
described in subsection (a) at least twice a week, and to swiftly
H. R. 6344—47
and certainly impose a known set of graduated sanctions for 
non-compliance with community-release provisions relating to 
drug abstinence (whether imposed as a pre-trial, probation, 
or parole condition or otherwise); 
‘‘(4) includes a strategy for responding to a range of sub-
stance use and abuse problems and a range of criminal his-
tories; 
‘‘(5) includes a plan for integrating data infrastructure 
among the agencies and organizations included in the eligible 
partnership to enable seamless, real-time tracking of individ-
uals described in subsection (a); 
‘‘(6) includes a plan to monitor and measure the progress 
toward reducing the percentage of the population of individuals 
described in subsection (a) who, upon being summoned for 
a drug test, either fail to show up or who test positive for 
drugs. 
‘‘(d) REPORTS TO CONGRESS.—
‘‘(1) INTERIM REPORT.—Not later than June 1, 2009, the 
Director shall submit to Congress a report that identifies the 
best practices in reducing the use of illicit drugs by chronic 
hard-drug users, including the best practices identified through 
the activities funded under this section. 
‘‘(2) FINAL
REPORT.—Not later than June 1, 2010, the 
Director shall submit to Congress a report on the demonstration 
programs funded under this section, including on the matters 
specified in paragraph (1). 
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There is authorized 
to be appropriated to carry out this section $4,900,000 for each 
of fiscal years 2007 through 2009.’’. 
SEC. 1120. POLICY RELATING TO SYRINGE EXCHANGE PROGRAMS. 
Section 703(a) (21 U.S.C. 1702(a)) is amended by adding at 
the end the following: 
‘‘When developing the national drug control policy, any policy of 
the Director relating to syringe exchange programs for intravenous 
drug users shall be based on the best available medical and sci-
entific evidence regarding their effectiveness in promoting indi-
vidual health and preventing the spread of infectious disease, and 
their impact on drug addiction and use. In making any policy 
relating to syringe exchange programs, the Director shall consult
H. R. 6344—48
with the National Institutes of Health and the National Academy 
of Sciences.’’.
Speaker of the House of Representatives.
Vice President of the United States and
President of the Senate.